ANXA1 and Anxiety: Overall, this study aims to (i) examine the preliminary efficacy of the WIT intervention in reducing SSD and/or SSA symptoms among community-dwelling older adults (primary outcome); (ii) examine the efficacy of WIT in improving life satisfaction, social connectedness (friendship), quality of life, and stress- and anxiety-related inflammatory outcomes (cortisol, annexin-A1, and interleukin-1β) among older adults with SSD and/or SSA (secondary outcomes); and (iii) evaluate the older adults’ perceptions and acceptability of the intervention through semistructured interviews.